Advertisement


Robert S. Miller, MD, on CancerLinQ: Big Data and Clinical Effectiveness

2017 Quality Care Symposium

Advertisement

Robert S. Miller, MD, of ASCO, updates the progress of CancerLinQ and its data set, now being used by oncologists to track quality measurement and reporting.



Related Videos

Breast Cancer

Caleb Dulaney, MD, on Breast Cancer: Improving Online Patient Information

Caleb Dulaney, MD, of the University of Alabama at Birmingham, discusses ways to broaden and improve the quality of information that women with breast cancer find—in English and Spanish—on websites of nationally recognized cancer centers (Abstract 135).

Issues in Oncology

Julie Bryar Porter, MS, on Improving Care: One Center’s Experience

Julie Bryar Porter, MS, of Stanford Health Care, discusses an approach to improving patient care with physician-led quality measures from diagnosis through end of life implemented at her academic cancer center (Abstract 49).

Issues in Oncology

Greg D. Judy, MD, on Safety Incidents in Radiotherapy

Greg D. Judy, MD, of UNC Health Care, discusses the contributing factors, and possible fixes, for near-miss and actual safety incidents in patients being treated with radiotherapy.

Issues in Oncology

Gabrielle Rocque, MD, on The Oncology Care Model: Transforming Practices

Gabrielle Rocque, MD, of the University of Alabama at Birmingham, discusses the challenges of implementing Oncology Care Model requirements, such as providing treatment plans, and the opportunities to transform practices with improved workflow and patient outcomes.

Issues in Oncology
Lung Cancer

Thomas J. Smith, MD, on Oral Abstract Session B (2017 Quality Care Symposium)

Thomas J. Smith, MD, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, summarizes two papers for which he was a discussant: reducing overuse of colony-stimulating factors without compromising the safety of patients with lung cancer receiving chemotherapy, and a cost-and-survival analysis before and after implementing Dana-Farber Clinical Pathways for patients with stage IV non–small cell lung cancer (Abstracts 3, 52).

Advertisement

Advertisement



Advertisement